Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 May;21(5):922-3.
doi: 10.1038/mt.2013.76.

Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system

Christopher Larson  1 , Natalie Mendez, Tony Reid
Affiliations
Comment

Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system

Christopher Larson et al. Mol Ther. 2013 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
p53 gene delivery with nanoparticles targeted to the transferrin receptor. SGT-53 selectively transfects cancer cells (below) relative to normal cells (above) due to high expression of the transferrin receptor. (Inset): Liposomal nanoparticle vector encoding wild-type p53 targeted with a single-chain antibody specific for the transferrin receptor.
See this image and copyright information in PMC

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Senzer N, Nemunaitis J, Nemunaitis D, Bedell C, Edelman G, Barve M.et al. (2013Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors Mol Ther 211096–1103. - PMC - PubMed
    1. Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ.et al. (2002Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes Mol Cancer Ther 1337–346. - PubMed
    1. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144–158. - PubMed
    1. Zhang Y, Satterlee A, Huang L. gene delivery by nonviral vectors: overcoming hurdles. In vivo. Mol Ther. 2012;20:1298–1304. - PMC - PubMed
    1. Audouy SL, de Leij LF, Hoekstra D, Molema G. characteristics of cationic liposomes as delivery vectors for gene therapy. In vivo. Pharm Res. 2002;19:1599–1605. - PubMed

Substances

LinkOut - more resources